Skip to main content
Clinical Trials/NCT05090644
NCT05090644
Completed
Not Applicable

Preventive and Personalized Medicine (2021-2023)

Asfendiyarov Kazakh National Medical University1 site in 1 country700 target enrollmentMarch 30, 2022
ConditionsSchizophrenia

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
Asfendiyarov Kazakh National Medical University
Enrollment
700
Locations
1
Primary Endpoint
number of SNPs associated with schizophrenia
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This is a GWAS study that aims to identify possible candidate genes associate to schizophrenia by exploring single nucleotide polymorphism (SNP) in a group of schizophrenia, in the Kazakh population. The investigators hypothesize that the careful phenotyping of the subject sand matching with increase the power to find SNP significantly associated with schizophrenia

Detailed Description

A genome-wide association study (GWAS) is an approach used in genetics research to associate specific genetic variations with particular diseases. The method involves scanning the genomes from many different people and looking for genetic markers that can be used to predict the presence of a disease. Once such genetic markers are identified, they can be used to understand how genes contribute to the disease and develop better prevention and treatment strategies.

Registry
clinicaltrials.gov
Start Date
March 30, 2022
End Date
January 20, 2023
Last Updated
3 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Asfendiyarov Kazakh National Medical University
Responsible Party
Principal Investigator
Principal Investigator

Ildar Fakhradiyev

Head of the Laboratory of Experimental Medicine

Asfendiyarov Kazakh National Medical University

Eligibility Criteria

Inclusion Criteria

  • persons of Kazakh nationality having this ethnicity in the 3rd generation
  • age from 18 to 65 years old;
  • the dispensary in a psychiatric institution at the place of residence with a diagnosis of "Paranoid schizophrenia";
  • the duration of the disease is at least 1 year (from the moment of taking under dispensary supervision):
  • absence of severe and chronic somatic diseases;
  • absence of severe and chronic neurological diseases;
  • absence of comorbid drug addiction pathology;
  • signed informed consent to conduct this study

Exclusion Criteria

  • persons of non-Kazakh nationality and Kazakh nationality, not confirmed until the 3rd generation
  • age less than 18 years old and over 65 years old;
  • those who are on dispensary registration in a psychiatric institution at the place of residence with a diagnosis not related to ICD-10 under the heading F20.0 "Paranoid schizophrenia";
  • having a disease duration of less than 1 year (from the moment of taking under dispensary supervision):
  • having severe and chronic somatic diseases;
  • having severe and chronic neurological diseases;
  • having comorbid narcological pathology;
  • not signed informed consent to conduct this study

Outcomes

Primary Outcomes

number of SNPs associated with schizophrenia

Time Frame: 1 year

Using GWAS to identify candidate genes associate with schizophrenia

Study Sites (1)

Loading locations...

Similar Trials